Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to know how sales of MicroPulse® laser consoles are trending or whether insiders are buying stock before new clinical data? This Iridex SEC filings hub starts where most ophthalmology investors begin—searching for hard-to-find data hidden in 10-Ks and 10-Qs. From cash flow tied to disposable probe sales to FDA-related 8-K disclosures, every document is organized and tagged so you can stop hunting and start analyzing.
Use Stock Titan’s AI to move straight to answers. Our algorithms deliver Iridex SEC filings explained simply: instant highlights of revenue by product line, flags on R&D spending changes, and side-by-side Iridex earnings report filing analysis. Need quick transaction intel? Receive Iridex Form 4 insider transactions real-time alerts that clarify Iridex executive stock transactions Form 4 in plain language. Each link opens the original EDGAR text plus an AI summary that answers common queries like “How did gross margin shift this quarter?” or “Which directors exercised options?”
- 10-K: The Iridex annual report 10-K simplified pinpoints consumable vs. console revenue and global distributor performance.
- 10-Q: Read the latest Iridex quarterly earnings report 10-Q filing with AI-generated trend notes.
- Form 4: Track Iridex insider trading Form 4 transactions moments after they post.
- 8-K: Critical announcements—Iridex 8-K material events explained without jargon.
- DEF 14A: The Iridex proxy statement executive compensation section highlights incentive alignment with glaucoma therapy milestones.
Whether you’re understanding Iridex SEC documents with AI for the first time or comparing quarter-over-quarter adoption of retina lasers, our real-time feed and concise commentary turn dense filings into actionable insights.
This Form 4/A is an amendment to a previously filed Form 4 for Scott Shuda, a Director of Iridex Corp (IRIX), reporting a stock option grant on June 13, 2025. The original filing was made on June 17, 2025.
Key details of the transaction:
- Granted 53,000 stock options to purchase common stock
- Exercise price set at $0.94 per share
- Options expire on June 13, 2032
- Vesting occurs at earlier of: one-year anniversary of grant date or 2026 annual stockholder meeting
The options were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. The filing was signed by Nilo De Castro as attorney-in-fact for Scott Shuda on June 24, 2025.
This Form 4/A filing amends a previously filed Form 4 dated June 17, 2025, reporting insider trading activity for Beverly A. Huss, a Director of Iridex Corp (IRIX). The amendment discloses a stock option grant that occurred on June 13, 2025.
Key details of the transaction:
- Granted 53,000 stock options to purchase common stock
- Exercise price set at $0.94 per share
- Options expire on June 13, 2032
- Vesting occurs at earlier of one-year anniversary or 2026 annual stockholder meeting
The stock options were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. The filing was signed by Nilo De Castro as attorney-in-fact for Beverly Huss on June 24, 2025.
Iridex Corp director William M. Moore received two stock option grants on June 13, 2025, as reported in this Form 4 filing:
- First grant: 53,000 stock options with exercise price of $0.94, vesting fully on either the one-year anniversary or 2026 annual meeting
- Second grant: 15,000 stock options with exercise price of $0.94, vesting monthly over four years starting July 13, 2025
Both options were granted under the company's 2008 Equity Incentive Plan and expire on June 13, 2032. The grants are exempt under Rule 16b-3. This compensation structure aligns the director's interests with shareholders through both short-term and long-term vesting schedules. The low exercise price suggests the stock may be trading near historical lows.
Iridex Corp CFO Romeo R. Dizon filed an amended Form 4 reporting two significant equity transactions on June 13, 2025:
- Acquired 22,500 Restricted Stock Units (RSUs) at $0.94 per share, with vesting over three years starting June 13, 2026 (one-third annually)
- Received stock options to purchase 75,000 shares of common stock at an exercise price of $0.94, vesting over three years and expiring June 13, 2032
Following these transactions, Dizon directly owns 37,745 shares and 75,000 stock options. This amended filing corrects a previous Form 4 filed on June 17, 2025. The equity awards were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. These grants appear to be part of executive compensation arrangements, demonstrating long-term alignment with shareholder interests through multi-year vesting schedules.
This Form 4/A amendment reports insider trading activity for Patrick Mercer, President and CEO of Iridex Corp (IRIX), correcting a filing from June 17, 2025. The transactions occurred on June 13, 2025 and include two key components:
- Restricted Stock Units (RSUs): Acquired 33,370 RSUs at $0.94 per share. These RSUs vest over three years, with one-third vesting annually starting June 13, 2026, contingent on continued service
- Stock Options: Granted rights to purchase 111,240 shares of common stock at an exercise price of $0.94 per share. These options vest over three years (one-third annually) and expire on June 13, 2032
Following these transactions, Mercer directly owns 420,100 shares. The equity awards were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. This compensation structure aligns the CEO's interests with long-term shareholder value through significant equity ownership requirements and performance incentives.
FAQ
What is the current stock price of Iridex (IRIX)?
What is the market cap of Iridex (IRIX)?
What is the core focus of Iridex Corporation?
Which technologies underpin Iridex's product portfolio?
How does Iridex generate revenue?
In which markets does Iridex operate?
What distinguishes Iridex's products from competitors?
Who are the primary customers of Iridex?
What kind of support does Iridex offer to its customers?
How is Iridex positioned in the competitive landscape?
